1 result
Filters • 3
Sort By
Results Per Page
Filters
1 result
3
Download the following citations:
Email the following citations:
Print the following citations:
Editor's Choice
  • Al-Otaibi T
  • Nagib AM
  • Halim MA
  • Abo-Atya H
  • Mahmoud T
  • et al.
Exp Clin Transplant. 2024 Jan;22(Suppl 1):323-331 doi: 10.6002/ect.MESOT2023.P112.
POPULATION:

Adult kidney transplant recipients with stable graft function (n= 247).

INTERVENTION:

Targeted haemoglobin of 11 to 12 g/dL with the use of erythropoietin-stimulating agents (ESA) (group 1, n= 183)

COMPARISON:

Targeted haemoglobin of 13 to 15 g/dL with ESA (group 2, n= 64)

OUTCOME:

Patients underwent monthly clinical and laboratory evaluations of kidney graft function. Quality of life and echocardiography were assessed at study start and at 12 months. In group 2, there were comparable post-transplant complications, but better graft function at 6 months and better cardiac indexes at 1 year of the study. At 12 months, quality of life had improved after full correction of post-transplant anaemia in the renal transplant recipients who received erythropoietin-stimulating agents.

OBJECTIVES:

Posttransplant anemia might be associated with cardiovascular morbidity and increased mortality. To our knowledge, the debate on anemia correction has neither been revisited nor decided definitively. We aimed to assess the effects of full correction of posttransplant anemia on the cardiovascular system and quality of life among renal transplant recipients with stable graft function who were using erythropoietin-stimulating agents.

MATERIALS AND METHODS:

We enrolled 247 kidney recipients with stable graft function to be assessed for anemia. Eligible patients were randomized to achieve targeted hemoglobin of 11 to 12 g/dL (group 1, n = 183) or of 13 to 15 g/dL (group 2, n = 64) with the use of erythropoietin-stimulating agents. Patients underwent monthly clinical and laboratory evaluations of kidney graft function. Quality of life and echocardiography were assessed at study start and at 12 months.

RESULTS:

The 2 groups were comparable regarding pretransplant characteristics. In group 2, we observed comparable posttransplant complications (P > .05) but better graft function at 6 months and better cardiac indexes at 1 year of the study (P < .05). At 12 months, quality of life had improved after full correction of posttransplant anemia in the renal transplant recipients who received erythropoietinstimulating agents.

CONCLUSIONS:

Full correction of posttransplant anemia in renal transplant recipients was associated with improved quality of life and cardiac indexes without an effect on cardiovascular comorbidity.